Get Ready, It’s Coming Next Week! What to Expect at COMPUTEX 2021
26.5.2021 10:36:00 EEST | Business Wire | Press release
COMPUTEX 2021 will be launched from May 31 to June 30. The organizer, the Taiwan External Trade Development Council (TAITRA), will roll out the #COMPUTEXVirtual platform to connect the technology community that breaks geographic limitations. COMPUTEX 2021 will offer an exceptional exhibition experience to attendees with the following highlights.
Highlight #1: Top Speakers Will Address on the Groundbreaking Technologies
COMPUTEX 2021 will kick off with the highly anticipated CEO Keynotes. From May 31 to June 2, key industry executives will discuss topics covering AI, high-performance computing (HPC), and other technology trends. Simon Segars, CEO of Arm, Dr. Lisa Su, President and CEO of AMD, Sanjay Mehrotra, President and CEO of Micron, Charles Liang, Founder, President and CEO of Supermicro, and Kurt Sievers, President and CEO of NXP Semiconductors are among the speaker lineup.
The COMPUTEX Forum on June 2 and 3 will revolve around the theme of "The New Era of Intelligence," focusing on key applications of AI, 5G, IoT, and electric vehicles. The forum will unlock the development of quantum computers and explore the infinite possibilities of future technology applications. The world's leading ICT experts will discuss business strategies and pulse industry trends in the post-pandemic era.
Highlight #2: Virtual Booths Will Showcase the Latest Products
#COMPUTEXVirtual, the all-new smart online platform, will use AI and automation technology to create an exceptional digital journey for users by providing a personalized interactive experience. Visitors will be able to obtain the latest product information in real-time.
Acer will showcase its very latest products and innovations that will be announced at its next@acer Global Press Conference to be held on May 27. It will also showcase solutions from its subsidiaries, including products for smart cities, AI, and enterprise use. ZOTAC, on the other hand, will be revealing a brilliant lineup of innovations, including the ZOTAC GAMING GeForce 3090 AMP Extreme Holo graphics card and the MAGNUS ONE ECM53060C mini PC.
Along with the big corporates, innovative startups are always the core elements to drive COMPUTEX and all the industry moving forward. The Epoch Foundation, committed to building partnerships in the global entrepreneurial community, has created a pavilion titled “Garage+ 46 Must-See Startups” on the #COMPUTEXVirtual platform. The exhibition is divided into three sections: “AI & Big Data,” “Digital Health & EdTech,” and “IoT & Energy.”
Moreover, #COMPUTEXVirtual builds #InnoVEXVirtual as a featured exhibit area to help startups connect with the international community. In addition to French Pavilion, Korean Pavilion, and the Dutch Pavilion, the European Bank for Reconstruction and Development (EBRD) is bringing 18 startups from 7 countries to join InnoVEX for the first time.
Highlight #3: Effective Online Platform Functions Will Synergize Matchmaking Opportunities
To maximize the benefits for exhibitors, #COMPUTEXVirtual will provide multiple effective, timely communication channels for exhibitors and visitors, such as video conferencing, meeting requests and instant messaging. Exhibitors can use AI technology to identify target audiences and promote products. Hyper-Personalized Recommendations will also help increase the matchmaking accuracy and enable companies to seize business opportunities effectively.
Together with the technology giants and disruptive startups, COMPUTEX 2021 is ready to bring the world an all-new digital experience. For more exhibition information, please visit the following:
- #COMPUTEXVirtual Online Exhibition Visitor Registration: https://virtual.computextaipei.com.tw/
- COMPUTEX CEO Keynote and COMPUTEX Forum Registration: https://virtual.computextaipei.com.tw/events/
About COMPUTEX TAIPEI (also called COMPUTEX):
Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.
About COMPUTEX 2021 Virtual:
As a pioneer in technology, COMPUTEX has been at the forefront in embracing digital transformation. In 2021, the show will go online. Together with the key global technology players, the organizer of COMPUTEX,Taiwan External Trade Development Council (TAITRA) introduces #COMPUTEXVirtual (including its global startups and innovations showcase #InnoVEXVirtual), an AI-driven virtual platform, and aims to deliver an exceptional virtual exhibition experience beyond the distance.
About TAITRA:
Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005459/en/
Contact information
For more updates：
COMPUTEX website: https://www.computextaipei.com.tw/
InnoVEX website : https://www.innovex.com.tw/
Press Contacts:
Ms. Tessa Lin <tessalin@taitra.org.tw
Ms. Li Chao < lichao@taitra.org.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom